Forecasting age-related macular degeneration through the year 2050: The potential impact of new treatments

Archives of Ophthalmology

Volumn 127, Issue 4, 2009, Pages 533-540

  Rein, David B ^a   Wittenborn, John S ^a   Zhang, Xinzhi ^a,b   Honeycutt, Amanda A ^a   Lesesne, Sarah B ^a   Saaddine, Jinan ^b  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VITAMIN; ZINC;

ARTICLE; BLINDNESS; CONTROLLED STUDY; FORECASTING; LOW LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RETINA MACULA AGE RELATED DEGENERATION; SIMULATION; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ATROPHY; BLINDNESS; CHOROIDAL NEOVASCULARIZATION; DATABASES, FACTUAL; EPIDEMIOLOGIC METHODS; EPIDEMIOLOGIC STUDIES; FEMALE; FORECASTING; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; MALE; MIDDLE AGED; MODELS, THEORETICAL; PHOTOCHEMOTHERAPY; PREVALENCE; RETINAL DISEASES; RETINAL PIGMENT EPITHELIUM; UNITED STATES; VISUALLY IMPAIRED PERSONS; VITAMINS;

EID: 65249101367     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.58     Document Type: Article

References (39)

1. American Academy of Ophthalmology(AAO). Age-Related Macular Degeneration, Preferred Practice Pattern: Limited Revision. San Francisco, CA: American Academy of Ophthalmology; 2006.
2. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
3. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485.
4. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754-1760.
5. Klein R, Klein BE,Tomany SC, MeuerSM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2002;109(10):1767-1779.
6. US Census Bureau Population Division. National Population Projections, Summary Tables:(NP-T4) Projections of the Total Resident Population by 5-Year Age Groups, Race, and Hispanic Origin With Special Age Categories: Middle Series, 1999 to2100. Washington, DC: US Census Bureau; 2000.
7. Macular Photocoagulation Study Group. Krypton laser photocoagulation forneo- vascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1990;108(6):816-824.
8. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neo- vascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol. 1993;111(9):1200-1209.
9. Age-Related Eye Disease Study Research Group. A randomized, placebo- controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
10. Bressler NM; Treatment of Age-Related Macular Degeneration With Photody- namic Therapy(TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related maculardegeneration with verteporfin: two- year results of 2 randomized clincal trials: TAP report 2. Arch Ophthalmol. 2001; 119(2):198-207.
11. Rein DB, Saaddine JB, Wittenborn JS, etal. Cost-effectiveness of vitamin therapy forage-related maculardegeneration. Ophthalmology. 2007;114(7):1319-1326.
12. SharmaS, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal chorodial neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001; 108(11):2051-2059.
13. Brown DM, Kaiser PK, Michels M, etal; ANCHOR Study Group. Ranibizumab versus verteporfin forneovascularage-related maculardegeneration. N Engl J Med. 2006;355(14):1432-1444.
14. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab(Avas- tin) therapy for neovascular age-related macular degeneration: twenty-four- week results of an uncontrolled open-label clinical study. Ophthalmology. 2006; 113(11):2002.e1-2002.e12.
15. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neo- vascular age-related macular degeneration: a systematic review. Br J Ophthalmol. 2007;91(9):1177-1182.
16. Rein DB, Saaddine JB, Wittenborn JS, et al. Technical appendix: cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology. 2007;114(7):e13-e20.
17. Ferris FL, Davis MD, ClemonsTE,etal; Age-Related Eye Disease Study(AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005;123(11):1570- 1574.
18. Davis MD, Gangnon RE, Lee LY, et al; Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report No. 17. Arch Ophthalmol. 2005;123(11):1484- 1498.
19. Klein R, Klein BE, Knudtson MD, etal. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006;113(3):373-380.
20. Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP; Los Angeles Latino Eye Study Group. Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology. 2004;111(7):1288-1297.
21. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related macu- lopathy lesions: the Blue Mountains Eye Study. Ophthalmology. 2002;109(6): 1092-1097.
22. Macular Photocoagulation Study Group. Argon laser photocoagulation for neo- vascular maculopathy: five year results from randomized clinical trials. Arch Ophthalmol. 1991;109(8):1109-1114.
23. Macular Photocoagulation Study Group. Laser photocoagulation forjuxtafoveal choroidal neovascularization: five year results from randomized clinical trials. Arch Ophthalmol. 1994;112(4):500-509.
24. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of sub- foveal choroidal neovascularization in Age-Related Macular Degeneration: two- year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol. 2001;131(5):541-560.
25. Chung PY, Schuman JS, Netland PA, Lloyd-Muhammad RA, Jacobs DS. Five- year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. Am J Ophthalmol. 1998;126(2): 185-190.
26. Friedman DS, KatzJ, BresslerNM, Rahmani B,Tielsch JM. Racial differences in the prevalence of age-related macular degeneration. Ophthalmology. 1999; 106(6):1049-1055.
27. Klein R, Klein BE, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-943.
28. Vingerling JR, Dielemans I, Hofman A, etal.The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205-210.
29. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology. 1995;102(10): 1450-1460.
30. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the Visual Impairment Project. Ophthalmology. 2000;107(8):1593-1600.
31. Charkoudian LD, GowerEW, Solomon SD, SchachatAP, BresslerNM, Bressler SB. Vitamin usage patterns in the prevention of advanced age-related macular degeneration. Ophthalmology. 2008;115(6):1032-1038.e4.
32. Klein BE, Knudtson MD, Lee KE, etal. Supplements and age-related eye conditions: the Beaver Dam Eye Study [published online ahead of print November 12, 2007]. Ophthalmology. 2008;115(7):1203-1208.
33. Chang CW, Chu G, Hinz BJ, Greve MD. Current use of dietary supplementation in patients with age-related macular degeneration. Can J Ophthalmol. 2003;38(1):27-32.
34. Ng WT, Goggin M. Awareness of and compliance with recommended dietary supplement among age-related macular degeneration patients. Clin Experiment Ophthalmol. 2006;34(1):9-14.
35. Viteyes. Vitamin Health Inc Web site. http://www.viteyes.com/. Accessed December 3, 2007.
36. Steinbrook R. The price of sight: ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14):1409-1412.
37. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab(Lucentis) versus bevacizumab(Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007; 91(9):1244-1246.
38. Peck P. Genentech eases stance on bevacizumab(Avastin) for macular degeneration. MedPageToday. November 1, 2007. http://www.medpagetoday. com/ProductAlert/Prescriptions/7191. Accessed February 11, 2009.
39. Mitka M. Study aims to clarify efficacy, safety of eye drug treatments. JAMA. 2007;297(14):1538-1539.